Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of ENHERTU for interstitial lung disease in unresectable/recurrent HER2-positive breast cancer
jRCT1080225197Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Started May 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1080225197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225197.